Management of Stage I Testicular Cancer

^aTotal testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH). CT: low-dose computed tomography.

^aHCG, AFP, LDH.
^bTotal testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH). CT: low-dose computed tomography.

Authors and Disclosures

Jerusha Padayachee^a, Roderick Clark^b, Padraig Warde^a and Robert J. Hamilton<sup>b

a</sup>Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto and ^bDivision of Urology, Department of Surgery, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Correspondence to
Robert J. Hamilton, MD, Staff Urologist, Associate Professor, Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, Canada M5G 2M9. Tel: +1 416 946 2909; fax: +1 416 946 6590; e-mail: rob.hamilton@utoronto.ca

Conflicts of interest
There are no conflicts of interest.

Sidebar

Key Points

• Active surveillance is the preferred approach for patients presenting with clinical stage I disease.

• Radiotherapy should be considered in low volume (<5 cm) relapsed seminoma to the retroperitoneum; chemotherapy is an option, while RPLND as an alternative strategy remains investigational.

• In appropriately selected patients, RPLND is an alternative to chemotherapy in relapsed nonseminomatous germ cell tumours.